diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5391diaendo-5391Research ArticleСтатьиArticlesОсновные результаты ADVANCE: клиническая интерпретация для эндокринологовMain results of the ADVANCE study: clinical interpretation for endocrinologistsЗалевскаяАлсу ГафуровнаZalevskyaAlsu Gafurovnaalsu-zalevskaya@mail.ruБабенкоА ЮBabenkoA Yu-ВолковаА РVolkovaA R-Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова200915062009122№2 (2009)1417Copyright © Залевская А.Г., Бабенко А.Ю., Волкова А.Р., 20092009Залевская А.Г., Бабенко А.Ю., Волкова А.Р.Zalevskya A.G., Babenko A.Y., Volkova A.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5391

Результаты ADVANCE приобретают особое значение. Могло показаться, что плохие новости исследования ACCORD могут поколебать уверенность специалистов в важности и необходимости достижения хорошего гликемического контроля при СД. Благодаря результатам исследования ADVANCE получены четкие доказательства того, что стратегия постепенного усиления сахароснижающей терапии с целью достижения целевого уровня гликированного гемоглобина (6,5%) безопасна и эффективна в отношении снижения риска поражения почек и макрососудистых исходов.

сахарный диабетфакторы риска сердечно-сосудистых заболеванийгликемияdiabetes mellitusrisk factors of cardiovascular diseasesglycemiaReferencesInternational Diabetes Federation. // Diabetes Atlas 3-rd Ed.Brussels: International Diabetes Federation, 2006.International Diabetes Federation. // Diabetes Atlas 3-rd Ed.Brussels: International Diabetes Federation, 2006.Anselmino M. et al. // Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected Diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. // Eur. Heart J., 2007, Dec 21: 18156611.Anselmino M. et al. // Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected Diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. // Eur. Heart J., 2007, Dec 21: 18156611.Gaede P et al. // Effect of multifactorial intervention on mortality in type 2 diabetes. // N.Engl. J.Med; 2008: 358: 580-591.Gaede P et al. // Effect of multifactorial intervention on mortality in type 2 diabetes. // N.Engl. J.Med; 2008: 358: 580-591.The Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. // The Seventh Report of the Joint National Committee: JNCVII Express. // JAMA, 2003: 289 (19) 2560:2572The Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. // The Seventh Report of the Joint National Committee: JNCVII Express. // JAMA, 2003: 289 (19) 2560:2572DCCT Research Group: The effect of intensive diabetes management on macrovascular events and risk factors in the DCCT. // Am.J.Cardiol. 1995; 75: 894-903.DCCT Research Group: The effect of intensive diabetes management on macrovascular events and risk factors in the DCCT. // Am.J.Cardiol. 1995; 75: 894-903.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet, 1998; 352: 837-853.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet, 1998; 352: 837-853.Mancia G.et al. // Systolic and diastolic blood pressure control in antihypertensive drug trials // J.Hypertens., 2002; 20: 1461-1464.Mancia G.et al. // Systolic and diastolic blood pressure control in antihypertensive drug trials // J.Hypertens., 2002; 20: 1461-1464.Dahlof B. et al. // For the ASCOT investigators. Prevention of Cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. // Lancet 2005, 366:895-906.Dahlof B. et al. // For the ASCOT investigators. Prevention of Cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. // Lancet 2005, 366:895-906.ADVANCE Collaborative Group. // Intensive Blood Glucose Control and vascular outcomes in patients with type 2 diabetes // N.Engl. J Med. 2008; 358: 2560-2572.ADVANCE Collaborative Group. // Intensive Blood Glucose Control and vascular outcomes in patients with type 2 diabetes // N.Engl. J Med. 2008; 358: 2560-2572.The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 Diabetes; // N.Engl. J.Med. 2008; 358: 2545-2559.The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 Diabetes; // N.Engl. J.Med. 2008; 358: 2545-2559.Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes; // N.Engl. J.Med. 2009, 360, l-ll.Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes; // N.Engl. J.Med. 2009, 360, l-ll.Zammitt N. N. et al. // Hypoglycemia in type 2 Diabetes. // Diabetes Care 2005; 28: 2948-2961.Zammitt N. N. et al. // Hypoglycemia in type 2 Diabetes. // Diabetes Care 2005; 28: 2948-2961.Miller C. D. et al. // Hypoglycemia in patients with type 2 diabetes mellitus. // Arch. Int. Med. 2005; 161: 1653-1659.Miller C. D. et al. // Hypoglycemia in patients with type 2 diabetes mellitus. // Arch. Int. Med. 2005; 161: 1653-1659.ADVANCE Collaborative Group. // Rationale and design of the ADVANCE Study: a Randomized trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 Diabetes mellitus. // J. Hypertens. 2001; 19, suppl. 4: S21-S28.ADVANCE Collaborative Group. // Rationale and design of the ADVANCE Study: a Randomized trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 Diabetes mellitus. // J. Hypertens. 2001; 19, suppl. 4: S21-S28.

The authors declare that there are no conflicts of interest present.